- Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S.
- Expands the GE Healthcare portfolio of contrast media products
Chalfont St Giles, UK – November 4 2019 – The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE Healthcare portfolio for U.S. patients and radiologists.